Laura D'Erasmo

MD, PhD

[Christie Ballantyne @CBallantyneMD]

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated CV protection in landmark head-to-head trial! Wow! Big news! Can’t wait to see the results at EASD ⁦@CMHC_CME⁩ ⁦@nationallipid⁩ ⁦@ASPCardio⁩ https://t.co/s6ss9YtOa4

[Laura D'Erasmo @Lauraderasmo]

Enjoy our last publication @_SimoneBini_
@FBarattaMD
@Tramontano_D
https://t.co/rEzwuFklns

[International Atherosclerosis Society (IAS) @atherosociety]

#Hypertriglyceridemia is independently associated with risk of atherosclerotic events, even when LDL-cholesterol levels appear controlled. This #INTERASPIRE study determined the frequency of HTG and residual combined dyslipidemia and their related factors in patients with coronary heart disease (CHD) from 13 countries across six World Health Organization (WHO) regions.

Read more: https://t.co/PeRRpPs4vo

[Francesco Barratta @FBarattaMD]

“Lipid-Lowering Therapy and Cardiovascular Prevention in Elderly”

A narrative review on one of the great challenges of our times.

https://t.co/e34jP0zhuT

[National Lipid Association @nationallipid]

New @lipidjournal article!📄 Check out our latest open access article on lomitapide treatment in patients with HoFH. Read it now👉https://t.co/WmiyFET6Wu

[National Lipid Association @nationallipid]

Authors: Marcello Arca, MD, @Lauraderasmo, Marina Cuchel, MD, PhD, Dirk Blom, PhD, Jaimini Cegla, PhD, FRCPath, P. Barton Duell, MD, @rauldsf_santos, Sallyann O'Brien, PhD

[SISA - Società Italiana Studio dell'Aterosclerosi @SISA_Atero]

📣 It’s spring time!
📆 6-8 April 2025
🎂 X edizione del meeting dedicato ai giovani ricercatori clinici e di base di #SISA #SIMI #SIIA #SID #SIPREC #SIGG.
Let’s meet, discuss, joint and enjoy!

https://t.co/8gMLMnqmq0

[Laura D'Erasmo @Lauraderasmo]

@SISA_Academy @kiaretta21 @Tramontano_D @_SimoneBini_ @Arca_Lab_ @AL_Catapano @baratta

[AJPC @AJPCardio]

Approximately 1 in 5 patients with possible FH who received any form of outreach as part of a QI program had a meaningful change in the management. Various process factors resulted in improved care. https://t.co/3eBicSLXCe @dramitkhera

[Felice Gragnano @FeliceGragnano]

📣 Clopidogrel outperforms aspirin as chronic monotherapy after PCI - better ischemic protection without increasing bleeding risk 👨‍⚕️💊

💥 P2Y12 inhibitors strike again! 💥

📌 SMART-CHOICE 3 is now online in @TheLancet 👉 https://t.co/BDC3cACUIl

@vlgmrc #Cardiology #ACC25

[Prof Kausik Ray FMedSci @ProfKausikRay]

Delighted to have presented the first Phase 2 trial of solbinsiran a siRNA targeting ANGPTL3 a key regular of Triglyceride metabolism. Despite ldl lowering patients with high TG have a high residual risk of CVD.

[Prof Kausik Ray FMedSci @ProfKausikRay]

The EAS FHSC is the largest only global registry of FH. I conceived the idea in 2015 and with a few colleagues started this. 10 years on it’s really starting to deliver important insights . Great editorial

[Laura D'Erasmo @Lauraderasmo]

Lipid lowering drugs in special population: focus on kidney disease. @Arca_Lab_
@Tramontano_D @_SimoneBini_
https://t.co/N6eLTvtBpZ

[Laura D'Erasmo @Lauraderasmo]

@SISA_Academy @Tramontano_D @Arca_Lab_

[Laura D'Erasmo @Lauraderasmo]

https://t.co/GBtR0c7bjy
Our latest effort is the result of an international collaboration focused on understanding the consequences of hypertriglyceridemia. #triglycerides #kidneydisease
@ATHjournal @_SimoneBini_

[Laura D'Erasmo @Lauraderasmo]

https://t.co/o1pQgAr9eE

[Ramon Bataller @rabataller]

Why some heavy drinkers don't develop cirrhosis ? The answer is in the genes.

This great article summarizes the hallmark research hits implicating PNPLA3 gene variations and individual susceptibility to alcohol-related cirrhosis.

https://t.co/fOcxOGsos2

[Atherosclerosis @ATHjournal]

Wear red to be seen, to be counted, to be heard, to make an impact. At Atherosclerosis we wear red every day #WearRedDay
@GoRedForWomen #GoRedforWomen #nationalgoredday @American_Heart @society_eas @atherosociety

[Federica Fogacci @FedericaFogacci]

Spotted in the very first EAS-LIPRA newsletter 📬 Great contribution @brettsmansfield! Can’t wait to read the preliminary results of your investigation on Lp(a) within African populations @society_eas #LIPRA #EASSoMe

[Laura D'Erasmo @Lauraderasmo]

Our last effort is now available on @ATHjournal. Understanding the differences in clinical and therapeutic management for men and women. @j_rvl @kiaretta21 @arturocesaro @Tramontano_D https://t.co/MnlH47ZWd1